Better Growth Stock: AbbVie vs. Abbott Laboratories

Drugmaker AbbVie (ABBV 0.38%) spun off from Abbott Laboratories (ABT 1.03%) at the start of 2013. The growth-oriented pharma business has become a beast, generating more than $58 billion in revenue last year -- far more than Abbott's top line, which totaled just under $44 billion.But today, AbbVie faces some challenges as its top-selling drug Humira is losing patent protection and its sales have been declining sharply. Abbott, meanwhile, isn't just some stale business. Its diabetes products have been genera ...